Coeptis Therapeutics Holdings, Inc.
COEPW
NASDAQ Global Market0.01
USD
- -
- -
CIK
0001759186
ISIN
US19207A1161
CUSIP
19207A116
Return %
Stock
S&P500
1Y
-56.67
26.53
3Y
-91.13
76.60
5Y
-98.07
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Mehalick
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 105 Bradford Road Wexford PA United States of America 15090
- IPO Date
- Dec 17, 2020
- CIK
- 0001759186
- Website
- coeptispharma.com
- Similar Companies
- Business
- Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. The company’s core products include the GEAR™ (Gene Edited Antibody Resistant) cell therapy platform; SNAP-CAR, a universal multi-antigen chimeric antigen receptor (CAR) T-cell technology licensed from the University of Pittsburgh; CD38-GEAR-NK, an autologous gene-edited natural killer cell platform; and companion diagnostics developed in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its therapeutic portfolio also features assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and the clinical-stage unmodified natural killer cell therapy DVX201. Coeptis operates primarily through its subsidiaries Coeptis Pharmaceuticals, GEAR Therapeutics, and SNAP Biosciences, with headquarters in Wexford, Pennsylvania. The company has recently undertaken significant strategic developments, including the acquisition of exclusive worldwide rights to the GEAR platform from Karolinska Institutet, the formation of GEAR Therapeutics as a majority-owned subsidiary to advance GEAR-NK into human trials, and completion of a $10 million Series A preferred stock offering in early 2025 followed by a private placement. Coeptis also announced a definitive merger agreement with Z Squared Inc., a cryptocurrency mining company, signaling a strategic diversification into next-generation technology sectors such as AI, blockchain, and digital transformation. This includes a partnership with NexGenAI Solutions Group to establish a technology hub in India focused on AI, blockchain, and robotic solutions for defense and security markets. These business expansions reflect a dual-track approach combining biotech innovation with technology-driven revenue generation. Founded in 2017, Coeptis has positioned itself in the oncology, autoimmune, and infectious disease segments with a focus on advancing novel cell therapies that offer potentially disruptive alternatives to conventional treatments. Its key markets include North America and Europe, supported by collaborations with leading academic and research institutions. The company was formerly operating under Bull Horn Holdings Corp. after a business combination in 2022 and trades on NASDAQ under the ticker COEP and warrants under COEPW. Recent operational highlights include enhanced capital structure through debt clearance and the planned spin-out of its biopharmaceutical operations as part of the Z Squared merger process. In summary, Coeptis Therapeutics Holdings develops and commercializes next-generation cell therapy platforms centered on gene-edited and universal CAR T technologies, with recent strategic moves into AI and blockchain-enabled technology solutions through partnerships, capital raises, and mergers aimed at expanding its product and service offerings beyond biopharmaceuticals into innovative technology-driven sectors.